Ensysce Biosciences, Inc. — Form 8-K/A
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 92/100
What the filing says
Ensysce completed acquisition of clinical-stage Cy Biopharma (developer of CY200 for Complex Regional Pain Syndrome with FDA Orphan Drug Designation) via stock-for-stock merger issuing 282,122 Series C Preferred shares (1:1,000 conversion ratio to common). Concurrent private placement raised $21.5M initial tranche and up to $38.6M milestone-based follow-on from Ally Bridge Group, Perceptive Advisors, Dellora, Ikarian Capital, and Adage Capital. Cy Biopharma founder James Morrison becomes President and Board member. Pro forma cash funds CY200 through Phase 2 data and into registration. Post-closing, Cy Biopharma shareholders own ~74.94%, new investors ~17.49%, and legacy Ensysce ~7.57% on fully diluted basis (equity value ~$122.9M excluding fees). Stockholder approval required for Series C conversion under Nasdaq rules.
Why this rating
Transformational for $5.3M market-cap company: $77M total financing + $17.1M acquired cash is ~14x current market value; dilutes existing shareholders to 7.57% but provides multi-year runway and late-stage pipeline asset. Clinical data, FDA orphan status, and experienced management substantially de-risk. Event materially alters trajectory.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.